Recent Updates
Recently added Catalysts

Dermacyd PH_DETINLYN

Phase 3

Hygiene | Small molecule | Other |Sanofi|Last Updated: Aug 25, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials3
Total Enrollment132

FDA Designations

No designations recorded

Clinical trial landscape

Dermacyd PH_DETINLYN · 3 trials · 1 indication

Phase 3 3
NCT00785590Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.Hygiene
COMPLETED26 Analytics
NCT00785655Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - CompatibilityHygiene
COMPLETED53 Analytics
NCT00786097Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - CompatibilityHygiene
COMPLETED53 Analytics
PHASE3COMPLETED
Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.
HygieneUnlock trial analytics
PHASE3COMPLETED
Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility
HygieneUnlock trial analytics
PHASE3COMPLETED
Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibility
HygieneUnlock trial analytics

Study Endpoints

Primary Endpoints

The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale
Throughout the study
The sensibility will be evaluated according to the skin type.
Throughout the study
The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.
Throughout the study
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeSUPPORTIVE_CARE

Treatment Arms

ArmTypeDescription
1EXPERIMENTALDermacyd PH\_DETINLYN (Lactic Acid)

Interventions

NameTypeDescription
Dermacyd PH_DETINLYN (Lactic Acid)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion criteria: * Phototype Skin II and III; * Integral skin test in the region; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: * Lactation or gestatio...

Countries:Brazil
Unlock Eligibility Criteria

Frequently asked questions about Dermacyd PH_DETINLYN

What is Dermacyd PH_DETINLYN used for?

Dermacyd PH_DETINLYN is a small molecule product used for hygiene purposes. It is being developed by Sanofi (ticker: SNY) and is currently in Phase 3 clinical development. The product contains lactic acid and is intended for use in hygiene applications, as studied in clinical trials.

Who makes Dermacyd PH_DETINLYN?

Dermacyd PH_DETINLYN is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials for this hygiene product, which is currently in Phase 3 development.

What phase is Dermacyd PH_DETINLYN in?

Dermacyd PH_DETINLYN is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. The Phase 3 trials have been completed, and the product is being studied for hygiene applications.

What clinical trials is Dermacyd PH_DETINLYN in?

Dermacyd PH_DETINLYN has been studied in three completed Phase 3 clinical trials: NCT00785590, NCT00785655, and NCT00786097. These trials evaluated the product's photo evaluation and compatibility in healthy female volunteers aged 18 years and older in Brazil.

Is Dermacyd PH_DETINLYN FDA approved?

Dermacyd PH_DETINLYN is not FDA approved. It is an investigational product currently in Phase 3 clinical development. The completed trials have been conducted in Brazil, and the product has not received regulatory approval in the United States or elsewhere.

What does Dermacyd PH_DETINLYN contain?

Dermacyd PH_DETINLYN contains lactic acid as its active ingredient. It is a small molecule product developed for hygiene purposes. The clinical trials evaluated the product's compatibility and photo evaluation in healthy female volunteers.